Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Arthritis, Rheumatoid 19Spondylitis, Ankylosing 6Psoriasis 4Colitis, Ulcerative 4Crohn Disease 3Inflammatory Bowel Diseases 2Uveal Melanoma 1Thyroid Carcinoma, Anaplastic 1Spondylarthritis 1Sarcoidosis 1Recurrence 1Plaque Psoriasis 1Osteoarthritis 1Nephrotic Syndrome 1Nephrosis, Lipoid 1Mucopolysaccharidosis VI 1Mucopolysaccharidosis II 1Mucopolysaccharidosis I 1Mucopolysaccharidoses 1Melanoma 1Macular dystrophy, corneal type 1 1Kidney Diseases 1Joint Diseases 1Inflammation 1Infections 1Hidradenitis Suppurativa 1Healthy Adult Male 1Healthy 1Glomerulosclerosis, Focal Segmental 1Dupuytren Contracture 1

Interventions

Vaginal Smears 1Tumor Necrosis Factor Inhibitors 1Radioimmunodetection 1Pregnancy Tests 1Human Papillomavirus DNA Tests 1Etanercept 1Adalimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Spondylarthritis × Adalimumab × Clear all
NCT02492217 2020-11-03

Biomarkers Identification of Anti-tumor Necrosis Factor (TNF) α Agent's Efficacy in Ankylosing Spondylitis Patients

Universidade Nova de Lisboa

Phase 4 Completed
69 enrolled

Spondylitis, Ankylosing, Spondylarthritis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡